±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2292  |  »Ø¸´: 12
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yalefield

½ð³æ (ÎÄ̳¾«Ó¢)

ÀϺºÒ»Ã¶

[½»Á÷] ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]

×÷ÕߣºJingyi

¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾­³£ÓÉÎüÑÌÓÕ·¢¡£

¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ­³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£

¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£

    ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2)
    µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£

¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾ­ÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£

Note:
1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561.
2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html
3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
4Â¥2007-12-19 14:13:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

wangw2008

½ð³æ (Ö°Òµ×÷¼Ò)

´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.

±¾ÈËÒ²Ò»Ö±ÔÚ»³ÒÉÕâ¸öÊý¾Ý£¬ÏÈÉùµÄËÄÆÚÁÙ´²Êý¾Ý×öµÄºÜ²î£¬ÖÁÓÚ£±£¬£²ÆÚµÄÊý¾ÝÔõôÀ´µÄ£®´ó¸ÅÖ»ÓÐÖйúµÄÕâ¸ö»·¾³Ï²Żá³öÏÖ£®
ÑÏÕýÉùÃ÷: ±¾ÌûÄÚÈÝÎ´Éæ¼°¹¥»÷ÈκγæÓÑ(°üÀ¨ÒÔָɣÂî»±£¬º¬É³ÉäÓ°µÈÐÎʽ),²»Ó°ÏìºÈѪ(ɽ¶«»°ºÍг)
2Â¥2007-12-19 07:07:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶¹¸ç

Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)

ÖÆÁ£ÄÜÊÖ

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÕâÑùµÄ»°Ò©ÎïûÓÐÁÆÐ§ÔõôÄÜÒ»Ö±ÔÚÁÙ´²ÉÏÓÃÄØ£¿
±ßѧ±ßÎÊ£¬²ÅÓÐѧÎÊ¡£
3Â¥2007-12-19 14:00:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
5Â¥2007-12-19 15:05:12
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 313Çóµ÷¼Á +3 º£ÈÕº£ÈÕ 2026-04-04 3/150 2026-04-05 07:48 by 544594351
[¿¼ÑÐ] 285Çóµ÷¼Á +8 ŶßϺôo 2026-04-04 8/400 2026-04-04 23:16 by lqwchd
[¿¼ÑÐ] 292·Ö£¬²ÄÁÏÓ뻯¹¤£¬ÉêÇëµ÷¼Á +22 ³ÌÇçÖ® 2026-04-01 26/1300 2026-04-04 22:03 by hemengdong
[¿¼ÑÐ] Ò»Ö¾Ô¸»¦9£¬ÇóÉúÎïѧµ÷¼Á£¬326·Ö +6 Áõīī 2026-04-04 6/300 2026-04-04 19:44 by ÌÆãå¶ù
[¿¼ÑÐ] Ò»Ö¾Ô¸»¦985£¬326·ÖÇóµ÷¼Á +3 Áõīī 2026-04-03 3/150 2026-04-04 11:16 by ±¯É˵ÄÓóÍ·
[¿¼ÑÐ] Çó²ÄÁϵ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ289·Ö +15 ˶ÐǸ° 2026-04-03 15/750 2026-04-04 01:01 by userper
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸±±Àí325·ÖÇóµ÷¼Á +6 ÕÒµ÷¼Á£¬£¬ 2026-04-02 6/300 2026-04-03 22:20 by –¹Æ?
[¿¼ÑÐ] 288Çóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó ²ÄÁÏÓ뻯¹¤ +39 ÂåÉñ¸ç¸ç 2026-03-31 41/2050 2026-04-03 21:51 by qlm5820
[¿¼ÑÐ] Çóµ÷¼Á +8 akdhjs 2026-04-03 8/400 2026-04-03 18:17 by ´÷άING
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤µ÷¼ÁÒ»Ö¾Ô¸´óÁ¬º£ÊÂ085600£¬349 +11 ³ÔµÄ²»ÉÙ 2026-03-30 11/550 2026-04-03 18:05 by Jimmyandyou
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +3 bvzz 2026-04-01 3/150 2026-04-03 09:47 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 22408 266Çóµ÷¼Á +3 masss11222 2026-04-02 3/150 2026-04-02 18:11 by ±ÊÂä½õÖÝ
[¿¼ÑÐ] ũѧ¿¼ÑÐÇóµ÷¼Á +3 dkdkxm 2026-04-01 3/150 2026-04-02 16:04 by wangjagri
[¿¼ÑÐ] 282Çóµ÷¼Á +13 ºôÎü¶¼ÊǼõ·Ê 2026-04-01 13/650 2026-04-02 14:10 by baoball
[¿¼ÑÐ] 349Çóµ÷¼Á +6 ³ÔµÄ²»ÉÙ 2026-04-01 6/300 2026-04-01 17:55 by JYD2011
[¿¼ÑÐ] Çóµ÷¼Á +4 DADA¹Ö 2026-03-31 4/200 2026-04-01 14:30 by ZXlzxl0425
[¿¼ÑÐ] 267Çóµ÷¼Á +13 uiybh 2026-03-31 13/650 2026-04-01 10:25 by ̽123
[¿¼ÑÐ] 080500-315·Ö¸´ÊÔµ÷¼Á +9 Éϰ¶3821 2026-03-31 9/450 2026-03-31 17:29 by ÌÆãå¶ù
[¿¼ÑÐ] Çóµ÷¼Á +8 11ggg 2026-03-30 8/400 2026-03-31 13:56 by nanaliuyun
[¿¼ÑÐ] 297 µØÀíѧ070500 ¸´ÊÔÇóµ÷¼Á +3 СԲȦȦooo 2026-03-30 3/150 2026-03-30 21:05 by ÓàÕðyz
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û